Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
48 studies found for:    Tardive Dyskinesia
Show Display Options
Download search resultsDownload the search results for:
Tardive Dyskinesia (48 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
Condition: Tardive Dyskinesia
Intervention: Device: Repetitive Transcranial Magnetic Stimulation
2 Completed NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
3 Completed A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
4 Completed Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: NBI-98854
5 Completed Piracetam for Treatment Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: piracetam
6 Completed Treatment of Tardive Dyskinesia With Galantamine
Condition: Tardive Dyskinesia
Intervention: Drug: Galantamine
7 Completed Tardive Dyskinesia and Cognitive Function
Conditions: Tardive Dyskinesia;   Neurocognitive Function
Interventions: Drug: amisulpride;   Drug: Olanzapine;   Drug: Conventional antipsychotics
8 Terminated Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: Pyridoxal 5'-Phosphate;   Drug: Placebo
9 Unknown  Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Dietary Supplement: Omega-3 fish oil capsules (including DHA);   Dietary Supplement: Placebo
10 Completed NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
11 Completed NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
12 Completed Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
Condition: Tardive Dyskinesia
Interventions: Drug: Melatonin;   Drug: Placebo
13 Completed Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
Condition: Neuroleptic-Induced Tardive Dyskinesia
Interventions: Drug: risperidone;   Drug: olanzapine
14 Completed Extract of Ginkgo Biloba and Tardive Dyskinesia
Conditions: Tardive Dyskinesia;   Schizophrenia
Interventions: Drug: Extract of Ginkgo Biloba (EGb-761 capsules);   Drug: Placebo
15 Active, not recruiting Reducing Involuntary Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: SD-809
16 Completed Addressing Involuntary Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: SD-809;   Drug: Placebo
17 Completed Aim to Reduce Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: SD-809;   Drug: Placebo
18 Completed A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
Condition: Drug-induced Tardive Dyskinesia
Interventions: Drug: SNC-102;   Drug: Placebo
19 Withdrawn Pyridoxal Kinase Activity in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: Pyridoxine
20 Completed Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Condition: Dyskinesia, Medication-induced
Intervention: Drug: Levetiracetam

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.